|Last Price||Today's Change||52-Week Range||Trading Volume|
|7.60||0.11 (+1.47%)||5.45 - 8.50||1.5 million (Below Avg)|
Market data as of 3:59PM 08/28/15. Quotes are delayed by at least 15 min.
Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
08/17/2015 7:00 AM ET